In recent years, novel therapies for rheumatoid arthritis have been developed including targeted small-molecule drugs and biologics. Today, RA has the broadest spectrum of biologic treatment options of any major disease, yet pharmaceutical companies continue to explore opportunities to enter this category.
Rheumatoid Arthritis Pipeline Perspectives Reports provide a comprehensive assessment of the drugs in development for RA by pathway target and mechanism of action.
Pipeline Analysis by Pathway Target and Mechanism of Action
“Vetted” and comprehensive list of drugs in development by pathway including a simple-to-understand synthesis of completed clinical trials and ongoing clinical studies
An understanding of how the drugs in development for a particular disease area compare to their potential future competition and the current standard-of-care
An overview of which therapies and pathways have recently failed in a particular disease area, providing insight into which pathways hold the greatest and least probability of future success
A slide library summarizing key findings for each pipeline agent by mechanism-of-action and target pathway
Reasons to Buy
Unlike many pipeline databases, our vetting process eliminates drugs that have been discontinued for development from the analysis, saving you significant time and effort
Comprehensive segmentation of disease pathway targets currently under investigation
Comprehensive explanation of how the product development efforts of specific companies are focused (e.g., IL-6, IL-12, etc.)
Assessment of how the drugs in development compare to drugs either on the market, in development in the same pathway, or relative to different mechanisms-of-action, based on clinical trial data
Timing of product launches of drugs in development, if approved
Detail around licensing terms for drugs in development, if applicable
Please note: The Online Download version of the report is for a Single Site License version – one location ONLY.